Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Spironolactone + vitamin E is a combination therapy consisting of the potassium-sparing diuretic spironolactone and the antioxidant vitamin E. This combination has been studied primarily for its effects in patients with non-alcoholic fatty liver disease (NAFLD). Spironolactone acts as a mineralocorticoid receptor antagonist, reducing sodium reabsorption and potassium excretion, while also exhibiting anti-androgenic properties. Vitamin E is an antioxidant that helps protect cells from oxidative damage. Clinical studies have shown that low-dose spironolactone combined with vitamin E can significantly decrease liver fat scores and improve insulin resistance in NAFLD patients compared to vitamin E alone[1][2][3][5]. The regimen may offer metabolic benefits but requires further large-scale trials to confirm efficacy and safety.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on spironolactone + vitamin e.